

Table of contents

PART I: Background, Status and Gaps

Filariae as organisms (including life cycles)
Human filariasis - disease and current problems
Canine filariasis (heartworm) - disease and current problems/gaps
diagnosis of human filarial infections
diagnosis of canine filarial infections
Antifilarial chemotherapy: current options (human section)
Antifilarial chemotherapy: current options (veterinary section)
Current products
Current antifilarial drug - mode of action
Drug resistance in canine filarial chemotherapy
Eradication/elimination of human filariae
The economic impact of human filariasis
The economic impact of canine filariasis

PART II: Antifilarial Drug Discovery and Development

Product profiles of new antifilarial drugs -
Discovery and development of new antifilarial drugs (in vitro assays)
Rodent models for the discovery of new antifilarial drugs
Discovery and development of new canine antifilarial drugs (in vivo assays)
Discovery and development of new human antifilarial drugs (in vivo assays)
The drug pipeline, including triple combination therapy, moxidectin, emodepside, TylaMac, auranofin

PART III: Alternative Approaches

Functional genomics of filariae
Vector control approaches: humans
Vector control approaches: canine
Drug targets at the host-parasite interface
Endosymbionts as targets
Vaccines: progress and prospects